Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung

Next Previous
X
Search
Trial Profile

A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Samotolisib (Primary) ; Necitumumab
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus First in man; Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 15 May 2018 Status changed to discontinued due to lack of activity as the observed DCR at 6 months is 4%, below the hypothesized 44% DCR at 6 months as the primary objective of this study.
    • 26 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.
    • 26 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top